Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Solomon SR et al. – Outpatient myeloablative allogeneic HSCT with expectant in–patient management can be accomplished safely with low treatment–related morbidity and mortality. Clinical outcomes seem comparable to those reported for traditional in–patient management.

Related Articles

Management of relapse after allo-SCT for AML and the role of second transplantation
Bone Marrow Transplantation, 10/29/09    Relevance Score: 41%

Implications of CD34+ cell dose on clinical and haematological outcome of allo-SCT for acquired aplastic anaemia
Bone Marrow Transplantation, 10/15/09    Relevance Score: 41%

5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis
Bone Marrow Transplantation, 10/15/09    Relevance Score: 40%

Association of HMGB1 Polymorphisms with Outcome after Allogeneic Hematopoietic Cell Transplantation
Biology of Blood and Marrow Transplantation, 10/14/09    Relevance Score: 40%

Cord blood transplantation in adults
Bone Marrow Transplantation, 10/07/09    Relevance Score: 40%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address